AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39262903
Drug: Merislon (Betahistine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merislon (Betahistine Mesilate Tablets)
Trial: 39263280
Drug: Intranasal esketamine
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intranasal esketamine 2 mg/kg (Group K)
Trial: 39263280
Drug: Esketamine 1
RxNorm normalized name: esketamine 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine 1 mg/kg and dexmedetomidine 1 µg/kg (Group KD1)
Trial: 39263280
Drug: Esketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine 0.5 mg/kg and dexmedetomidine 2 µg/kg (Group KD2)
Trial: 39263597
Drug: Twice-nightly immediate-release
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-nightly immediate-release (IR) oxybate
Trial: 39263892
Drug: Pressurized intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with nab-paclitaxel plus systemic gemcitabine, cisplatin, and durvalumab (gem/cis/durva)
Trial: 39263892
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment comprising gemcitabine, cisplatin, and durvalumab (gem/cis/durva)
Trial: 39264108
Drug: eHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eHealth intervention group (12 interactive modules on PA, DB, and sleep delivered weekly)
Trial: 39264108
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (weekly brochures on PA, DB, and sleep recommendations)
Trial: 39264438
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 70 µg/day (2800 IU)
Trial: 39264438
Drug: Antithyroid drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drugs (ATD)
Trial: 39264503
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of atorvastatin
Trial: 39264535
Drug: Glenohumeral hydrodistension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glenohumeral hydrodistension combined with bursal injection
Trial: 39264599
Drug: MYL-1701P (0.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MYL-1701P (0.5-mg vial) every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52
Trial: 39264599
Drug: Reference aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reference aflibercept every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52
Trial: 39761483
Drug: Datopotamab deruxtecan
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Datopotamab deruxtecan (Dato-DXd) 6 mg/kg once every 3 weeks
Trial: 39265161
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine diagnostic tools
Trial: 39265161
Drug: Health Evaluation
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health Evaluation Questionnaire, Physical Activity Questionnaire, sugar intake assessment, Constitution in Chinese Medicine Questionnaire, radial pulse diagnosis, and tongue diagnosis
Trial: 39265466
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and Carboplatin (PC) - 6 cycles of P 175 mg/m2 and C AUC=6 IV every 3 weeks
Trial: 39265466
Drug: Bleomycin, Etoposide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin, Etoposide, and Cisplatin (BEP) - 4 cycles of B 20 units/m2 IV push day 1, E 75 mg/m2 IV days 1-5, and Cisplatin 20 mg/m2 IV days 1-5 every 3 weeks
Trial: 39265579
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously every 21 days until disease progression or unacceptable toxicity.
Trial: 39265613
Drug: fedratinib 400
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fedratinib 400 mg per day
Trial: 39265613
Drug: best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: best available therapy (BAT)
Trial: 39266309
Drug: Colchicine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5 mg QD orally for 3 days before surgery and 0.5 mg QOD for 10 days after surgery)
Trial: 39266309
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch tablets for the same time and dosage)
Trial: 39266308
Drug: Intranodal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranodal administration of tolDCs loaded with heat shock protein 70-derived peptide mB29a, two intranodal injections of 5×10 (dosage not fully specified)
Trial: 39266619
Drug: DP303c administered
RxNorm normalized name: ADC DP303c
DrugBank: DP-303c (DB17212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP303c administered intravenously every 3 weeks at doses of 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 3.0 mg/kg, and 4.0 mg/kg.
Trial: 39266747
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination of HIV-1 broadly neutralizing antibodies (bNAbs)
Trial: 39266747
Drug: Monotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy or cocktail of two antibodies
Trial: 39266862
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with Chinese herbal medicine (chemo+CHM)
Trial: 39266862
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with placebo (chemo+placebo)
Trial: 39266938
Drug: Online biopsychobehavioral
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online biopsychobehavioral rehabilitation study including phosphodiesterase-5 inhibitors, sexual aids, pelvic floor exercise regimen, video, guide to good gay sex, and coaching.
Trial: 39266961
Drug: Escalating doses
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of CBD (5 mg CBD/kg/day to 30 mg CBD/kg/day, escalated every two weeks in increments of 5 mg CBD/kg/day)
Trial: 39266985
Drug: Root Canal
RxNorm normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Root Canal Treatment (RCT)
Trial: 39267085
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups receive concurrent chemotherapy with capecitabine and consolidation chemotherapy of either two cycles of CAPEOX or three cycles of FOLFOX between radiotherapy and surgery
Trial: 39267574
Drug: Inosine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine (0.2 g, three times/day) + PD-1/PD-L1 inhibitor
Trial: 39267574
Drug: Non-inosine (PD-1/PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-inosine (PD-1/PD-L1 inhibitor ± targeted ± chemotherapy)
Trial: 39267685
Drug: Personalized mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized mRNA vaccine (1 mg every 3 weeks for 4 cycles) combined with PD-1 inhibitor therapy.
Trial: 39267685
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor therapy (single dose 8 weeks after the 4th cycle).
Trial: 39268119
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy (Venturi mask or nasal goggles) after early extubation for 48 hours
Trial: 39268699
Drug: Single 300-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 300-mg dose of bepirovirsen in participants with hepatic impairment (HI)
Trial: 39268857
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg)
Trial: 39268981
Drug: Pegaspargase, etoposide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy (IFRT)
Trial: 39269742
Drug: Self-Care Self-Efficacy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-Care Self-Efficacy Index in Oral Anticoagulation Therapy Management (SCSE-OAC)
Trial: 39270151
Drug: Clopidogrel-aspirin (days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-aspirin (days 1-21) followed by clopidogrel (days 22-90)
Trial: 39270151
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone for 90 days
Trial: 39270380
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab with chemotherapy
Trial: 39270686
Drug: Once-weekly insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly insulin efsitora alfa
Trial: 39270695
Drug: Savolitinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib 600 mg once daily for patients with bodyweight ≥50 kg; 400 mg once daily for patients with bodyweight <50 kg, administered in 21-day cycles.
Trial: 39270701
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of the intervention (specific intervention not provided in the abstract)
Trial: 39270702
Drug: Atezolizumab, venetoclax,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab, venetoclax, and obinutuzumab combination
Trial: 39270828
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) for oligoprogressive disease in 1 to 5 fractions while maintaining systemic therapy (ST)
Trial: 39271104
Drug: Subcutaneous daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous daptomycin (10 mg/kg)
Trial: 39271104
Drug: Intravenous daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous daptomycin (10 mg/kg)
Trial: 39271104
Drug: Subcutaneous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous placebo (NaCl 0.9%)
Trial: 39271158
Drug: Somapacitan and
RxNorm normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Somapacitan and Daily GH
Trial: 39271928
Drug: ICVB-1042 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICVB-1042 administered intravenously or intratumorally
Trial: 39271928
Drug: ICVB-1042 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICVB-1042 administered intravenously
Trial: 39272058
Drug: F-627 (efbemalenograstim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-627 (efbemalenograstim alfa) 20 mg once per cycle
Trial: 39272058
Drug: Filgrastim (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (5 µg/kg/d) daily
Trial: 39272164
Drug: Cooperative medication
RxNorm normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooperative medication reviews conducted by MipAC physicians, supervised by geriatricians, and in collaboration with general practitioners
Trial: 39272164
Drug: Cooperative medication
RxNorm normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooperative medication reviews
Trial: 39272210
Drug: Transdiagnostic Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic Cognitive Remediation Therapy (TCRT)
Trial: 39272232
Drug: Positive CD
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive CD serology screening for antitissue transglutaminase antibodies in individuals with predisposing HLA-DQ2/DQ8 genotypes.
Trial: 39273147
Drug: Treatment-resistant CHCs
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-resistant CHCs
Trial: 39276176
Drug: MK-8353 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8353 plus pembrolizumab (arm A; MK-8353 50-350 mg twice daily)
Trial: 39276176
Drug: MK-8353 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8353 plus pembrolizumab (arm B; MK-8353 50-600 mg once daily)
Trial: 39276176
Drug: MK-8353 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8353 plus pembrolizumab (arm C; MK-8353 50-300 mg once daily every other week)
Trial: 39276185
Drug: Iparomlimab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iparomlimab (3 mg/kg, intravenous, once every 3 weeks)
Trial: 39276619
Drug: Ad26.RSV.preF/RSV preF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.RSV.preF/RSV preF protein vaccine (different doses of Ad26.RSV.preF with fixed dose of RSV preF protein 150 μg)
Trial: 39276782
Drug: Real-time estimation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time estimation of antibody kinetics against SARS-CoV-2 variants (delta, BA.2, XBB 1.5)
Trial: 39276782
Drug: Real-time dataset
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time dataset of neutralising-antibody titres
Trial: 39276782
Drug: Retrospective dataset
RxNorm normalized name: octinoxate 0.25 g in 50 mL / avobenzone 0.15 g in 50 mL / octocrylene 0.4 g in 50 mL TOPICAL LOTION [retrospect day shield broad spectrum SPF 25]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective dataset of neutralising-antibody titres
Trial: 39276785
Drug: Sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200 mg) and bevacizumab (15 mg/kg) intravenously every 3 weeks until disease progression
Trial: 39277671
Drug: Sequential multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential multiple assignment randomization trial design including three blocks: block A (experimental agent), block B (taxane-based regimen), block C (doxorubicin-cyclophosphamide)
Trial: 39277739
Drug: Quadrivalent influenza
RxNorm normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent influenza vaccine (15 µg/subtype/0.5 ml/dose)
Trial: 39278126
Drug: Function-focused multicomponent
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Function-focused multicomponent exercise program (twice-weekly for 6 months)
Trial: 39278411
Drug: Vitamin D-3
RxNorm normalized name: Vitamin D-3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D-3 supplementation (3000 IU daily)
Trial: 39278994
Drug: Nivolumab (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (480 mg) plus Relatlimab (480 mg) for two 4-weekly cycles
Trial: 39279257
Drug: 5-mg dose
RxNorm normalized name: diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-mg dose of melatonin 1 hour before bedtime for 6 weeks
Trial: 39279266
Drug: Autologous Bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Bone Marrow Aspirate Concentrate (BMAC) injection during APM
Trial: 39279580
Drug: Darolutamide 600
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide 600 mg twice daily plus androgen-deprivation therapy (ADT)
Trial: 39279580
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus androgen-deprivation therapy (ADT)
Trial: 39279639
Drug: Cagrilintide (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cagrilintide (4.5 mg, once-weekly subcutaneous injection)
Trial: 39279639
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg, oral)
Trial: 39279719
Drug: Lutein (L)
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lutein (L) and zeaxanthin (Z) concentrations measured by HPLC
Trial: 39280785
Drug: Multiple electroacupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple electroacupuncture weekly treatment group (group M) - 12 sessions (3 sessions per week)
Trial: 39280785
Drug: Single electroacupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single electroacupuncture weekly treatment group (group S) - 4 sessions (1 session per week)
Trial: 39280787
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg subcutaneously
Trial: 39281757
Drug: Integrated ML
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated ML models using lifestyle factors
Trial: 39281809
Drug: European Organization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Sexual Health
Trial: 39281809
Drug: European Organization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire
Trial: 39281971
Drug: Subcutaneous sasanlimab
RxNorm normalized name: Sasanlimab
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous sasanlimab 300 mg once every 4 weeks (300 mg-Q4W)
Trial: 39281971
Drug: Subcutaneous sasanlimab
RxNorm normalized name: Sasanlimab
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous sasanlimab 600 mg once every 6 weeks (600 mg-Q6W)
Trial: 39282041
Drug: Prophylactic infusion
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic infusion of calcium gluconate
Trial: 39282896
Drug: Chemotherapy (physician's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (physician's choice)
Trial: 39282897
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks)
Trial: 39282897
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks plus placebo)
Trial: 39282897
Drug: Ipilimumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3 mg/kg every 3 weeks for four doses plus placebo)
Trial: 39282905
Drug: Preoperative chemoradiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiotherapy plus perioperative chemotherapy
Trial: 39282905
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy alone (control)
Trial: 39282905
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (control)
Trial: 39283234
Drug: Individualized, goal-oriented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized, goal-oriented intervention; details on dosage and duration not specified.
Trial: 39283290
Drug: Itacitinib 400
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib 400 mg orally daily, 28-day cycle
Trial: 39284329
Drug: Tivozanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib plus nivolumab (0.89 mg per day orally + 480 mg every 4 weeks intravenously)
Trial: 39284329
Drug: Tivozanib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib monotherapy (1.34 mg per day orally)
Trial: 39284329
Drug: Tivozanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib plus nivolumab (for patients with ICI as immediate previous therapy)
Trial: 39284329
Drug: Tivozanib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib monotherapy (for patients with ICI as immediate previous therapy)
Trial: 39284329
Drug: Tivozanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib plus nivolumab (for patients with non-ICI as immediate previous therapy)
Trial: 39284329
Drug: Tivozanib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib monotherapy (for patients with non-ICI as immediate previous therapy)
Trial: 39284329
Drug: Tivozanib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib monotherapy
Trial: 39284337
Drug: Belzutifan 120
RxNorm normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belzutifan 120 mg once daily until unacceptable toxicity, disease progression, or patient decision to withdraw.